Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20160123
Arvisais E, et al. (2010) Prostaglandin F2alpha represses IGF-I-stimulated IRS1/phosphatidylinositol-3-kinase/AKT signaling in the corpus luteum: role of ERK and P70 ribosomal S6 kinase. Mol Endocrinol 24, 632-43 20160123
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
rapamycin dinoprost no effect upon treatment-induced increase
U0126 dinoprost inhibit treatment-induced increase
U0126, rapamycin dinoprost inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
rapamycin dinoprost no effect upon treatment-induced increase
U0126 dinoprost inhibit treatment-induced increase
U0126, rapamycin dinoprost inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
rapamycin dinoprost no effect upon treatment-induced increase
U0126 dinoprost inhibit treatment-induced increase
U0126, rapamycin dinoprost inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
rapamycin dinoprost no effect upon treatment-induced increase
U0126 dinoprost inhibit treatment-induced increase
U0126, rapamycin dinoprost inhibit treatment-induced increase

S312-p - IRS1 (human)
Modsite: tEsItAtsPAsMVGG SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S312‑p, IRS1 (mouse): S307‑p, IRS1 (rat): S307‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
dinoprost increase
rapamycin dinoprost inhibit treatment-induced increase
U0126 dinoprost inhibit treatment-induced increase
U0126, rapamycin dinoprost inhibit treatment-induced increase

S616-p - IRS1 (human)
Modsite: DDGyMPMsPGVAPVP SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S616‑p, IRS1 (mouse): S612‑p, IRS1 (rat): S612‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
dinoprost increase
rapamycin dinoprost inhibit treatment-induced increase
U0126 dinoprost inhibit treatment-induced increase
U0126, rapamycin dinoprost inhibit treatment-induced increase

S636-p - IRS1 (human)
Modsite: sGDyMPMsPKsVSAP SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S636‑p, IRS1 (mouse): S632‑p, IRS1 (rat): S632‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
dinoprost increase
rapamycin dinoprost inhibit treatment-induced increase
U0126 dinoprost inhibit treatment-induced increase
U0126, rapamycin dinoprost inhibit treatment-induced increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
dinoprost increase
rapamycin dinoprost inhibit treatment-induced increase
U0126 dinoprost no effect upon treatment-induced decrease
U0126, rapamycin dinoprost inhibit treatment-induced increase

T444-p - p70S6K (human)
Modsite: RFIGsPRtPVsPVkF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
rapamycin dinoprost inhibit treatment-induced increase partial inhibition
U0126 dinoprost inhibit treatment-induced increase partial inhibition
U0126, rapamycin dinoprost inhibit treatment-induced increase

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
dinoprost increase
rapamycin dinoprost inhibit treatment-induced increase
U0126 dinoprost no effect upon treatment-induced decrease
U0126, rapamycin dinoprost inhibit treatment-induced increase

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost increase
dinoprost increase
rapamycin dinoprost inhibit treatment-induced increase
U0126 dinoprost no effect upon treatment-induced decrease
U0126, rapamycin dinoprost inhibit treatment-induced increase

T308-p - Akt1 (cow)
Modsite: KDGATMKtFCGTPEY SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost decrease
IGF-1 increase
dinoprost IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
rapamycin IGF-1 no effect upon treatment-induced increase
U0126 IGF-1 no effect upon treatment-induced increase
rapamycin dinoprost, IGF-1 inhibit treatment-induced decrease
U0126 dinoprost, IGF-1 inhibit treatment-induced decrease

S473-p - Akt1 (cow)
Modsite: RPHFPQFsYSASATA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'granulosa, luteal'
Cellular systems studied:  primary cells
Species studied:  cow
Comments:  luteal cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
dinoprost decrease
IGF-1 increase
dinoprost IGF-1 inhibit treatment-induced increase
wortmannin IGF-1 inhibit treatment-induced increase
rapamycin IGF-1 no effect upon treatment-induced increase
U0126 IGF-1 no effect upon treatment-induced increase
rapamycin dinoprost, IGF-1 inhibit treatment-induced decrease
U0126 dinoprost, IGF-1 inhibit treatment-induced decrease